Synthesis and characterisation of biomimetic immunostimulatory lipid-polymer hybrid nanoparticles

Abstract

Tuberculosis (TB), caused by Mycobacterium tuberculosis (M. tuberculosis), remains a fatal infectious disease and one of the top ten leading causes of mortality, particularly in developing countries. Current drug therapy for TB is challenged by the poor physiochemical properties of the antibiotics used. These properties impact their bioavailability, toxicity, and treatment duration, thereby negatively impacting patient adherence. These factors also contribute to the emergence of the difficult to treat multi-drug resistant strains of M. tuberculosis. Recently, immunotherapy has emerged as a promising alternative treatment modality for TB.